Related Experiment Videos
[Angina pectoris: the lipid profile and clinical practice]
1U.T.I.C-Arsénio Cordeiro, Hospital de Santa Maria, Lisboa.
Acta Medica Portuguesa
|April 1, 1997
Summary
This study reviews lipid-lowering therapy for coronary artery disease (CAD) prevention, highlighting findings from the 4S, CARE, and West of Scotland studies for secondary and primary prevention strategies.
Area of Science:
- Cardiovascular Medicine
- Pharmacology
Context:
- Coronary artery disease (CAD) remains a leading cause of mortality worldwide.
- Lipid-lowering therapies have evolved significantly, impacting CAD management.
- Recent clinical trials provide critical data on the efficacy of these therapies.
Purpose:
- To provide a historical overview of lipid-lowering therapy in relation to CAD.
- To discuss current issues in secondary prevention of CAD based on recent studies.
- To examine primary prevention strategies for CAD in light of new evidence.
Summary:
- The 4S (Scandinavian Simvastatin Survival Study) and CARE (Cholesterol and Recurrent Events) trials demonstrated significant benefits of statin therapy in secondary CAD prevention.
- The West of Scotland Study provided insights into the role of lipid-lowering therapy in primary prevention of CAD.
- Current evidence supports the use of lipid-lowering agents for both preventing initial CAD events and reducing recurrence.
Impact:
- This review synthesizes key findings from landmark trials, informing clinical practice guidelines.
- It emphasizes the importance of evidence-based lipid management for improving cardiovascular outcomes.
- The discussion aids healthcare professionals in optimizing therapeutic strategies for CAD prevention.